Jynarque 15MG/45MG
Ended Awarded
- Contract number
- 36C24621N0913
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 6
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $10,304
Award facts
- Contract value 100% obligated
- $10,303.55 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
About this award
On June 22, 2021, the Department of Veterans Affairs, Veterans Integrated Service Network 6, awarded a firm fixed-price delivery order to Otsuka America Pharmaceutical Inc. for $10,303.55 for the supply of Jynarque 15mg/45mg tablets. Jynarque (tolvaptan) is a specialized pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veteran populations. The delivery order is set to be completed by July 1, 2021, with performance occurring in Pittsburgh, Pennsylvania. This award was issued without a set-aside designation, reflecting the contractor's status as an established large pharmaceutical manufacturer.
This delivery order is issued under Otsuka America Pharmaceutical Inc.'s broader Blanket Purchase Agreement with the VA's National Acquisition Center for Jynarque, valued at $83.3 million and expiring March 26, 2026, issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The BPA enables VA facilities across multiple Integrated Service Networks to efficiently procure this critical medication for veterans. Otsuka America Pharmaceutical maintains an established federal contracting presence with the VA, supported by its $396 million Federal Supply Schedule contract for pharmaceuticals and hematology-related products, positioning the company as a key supplier of specialized pharmaceutical treatments to the veterans healthcare system nationwide.
Quick answers
Who was awarded contract 36C24621N0913?
36C24621N0913 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 6 (Veterans Health Administration) on June 22, 2021.
How much is contract 36C24621N0913 worth?
The government has obligated $10,304 on 36C24621N0913.
Is contract 36C24621N0913 an order under another contract?
Yes. 36C24621N0913 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24621N0913 competed?
The extent of competition for 36C24621N0913 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award